Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$45.84, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 35x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 6.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$83.42 per share. Live News • May 20
WuXi XDC Cayman Launches US$100 Million Share Buyback to Support Employee Schemes WuXi XDC Cayman announced a voluntary on-market share purchase plan of up to US$100 million to support its share schemes and employee compensation plans.
The Board stated it views the current share price as undervaluing the company and sees the plan as an opportunity to buy shares at what it considers a favorable level.
Management indicated the purchases will comply with regulatory requirements and are intended to support shareholder value while maintaining financial stability.
The key signal here is confidence from the Board, which is willing to allocate up to US$100 million to buy back stock for employee-related programs at current prices.
You should still weigh how this capital use fits with your expectations for WuXi XDC Cayman's cash needs, growth plans and any alternative uses of funds such as investment or debt reduction. Reported Earnings • Apr 26
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥1.22 (up from CN¥0.89 in FY 2024). Revenue: CN¥5.94b (up 47% from FY 2024). Net income: CN¥1.48b (up 38% from FY 2024). Profit margin: 25% (down from 26% in FY 2024). The decrease in margin was driven by higher expenses. Products in clinical trials Phase I: 86 Phase II: 18 Phase III: 23 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Hong Kong. Recent Insider Transactions Derivative • Apr 15
CEO & Executive Director exercised options to buy HK$64m worth of stock. On the 8th of April, Jincai Li exercised options to buy 1m shares at a strike price of around HK$1.80, costing a total of HK$1.8m. This transaction amounted to 67% of their direct individual holding at the time of the trade. Jincai currently holds less than 1% of total shares outstanding. Company insiders have collectively bought HK$1.2m more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Apr 01
WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders. WuXi XDC Cayman Inc. (SEHK:2268) proposed to acquire 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders for HKD 1.9 billion on January 14, 2026. A cash consideration valued at HKD 4 per share will be paid by WuXi XDC Cayman Inc.
The Board of Directors of BioDlink International Company Limited formed a special committee for the transaction. The transaction is subject to minimum tender.
The transaction is expected to close on March 27, 2026. As of March 13, 2026 The Offeror received valid acceptances for 46.54% of the company's issued share capital by the first closing date. However, the acceptance condition of holding at least 60% of voting rights was not met, leading to an extension of the offer to March 27, 2026. As of March 17, 2026, the Offeror had received valid acceptances for the Share Offer in respect of 463,672,734 Offer Shares, representing approximately 60% of the total issued share capital of BioDlink International Company Limited. the Offeror had received valid acceptances for the Option Offer in respect of 6,512,600 Share Options representing approximately 85.33% of the total outstanding Share Options. The transaction is expected to close on March 31, 2026.
Citigroup Global Markets Asia Limited acted as financial advisor for WuXi XDC Cayman Inc. Grand Moore Capital Limited act as financial advisor for special committee. Tricor Investor Services Limited acted as Registrar to BioDlink International Company Limited. Grand Moore Capital Limited acted as financial advisor to independent board committee of BioDlink International Company Limited.
WuXi XDC Cayman Inc. (SEHK:2268) completed the acquisition of 60% stake in BioDlink International Company Limited (SEHK:1875) from a group of shareholders on March 31, 2026. Reported Earnings • Mar 24
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥1.22 (up from CN¥0.89 in FY 2024). Revenue: CN¥5.94b (up 47% from FY 2024). Net income: CN¥1.48b (up 38% from FY 2024). Profit margin: 25% (down from 26% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Life Sciences industry in Hong Kong. Announcement • Mar 23
WuXi XDC Cayman Inc., Annual General Meeting, Jun 26, 2026 WuXi XDC Cayman Inc., Annual General Meeting, Jun 26, 2026. Recent Insider Transactions Derivative • Jan 28
CEO & Executive Director exercised options to buy HK$98m worth of stock. On the 21st of January, Jincai Li exercised options to buy 2m shares at a strike price of around HK$1.80, costing a total of HK$2.7m. As of today, Jincai currently holds no shares directly. Company insiders have collectively sold HK$573k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jan 23
WuXi XDC Cayman Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026 WuXi XDC Cayman Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026 Announcement • Jan 16
Wuxi Xdc Cayman Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025 WuXi XDC Cayman Inc. provided unaudited consolidated earnings guidance for the year ended December 31, 2025. For the year, The Group is expected to record the following financial results for the year ended December 31, 2025: Revenue: an increase of more than 45% as compared to the year ended December 31, 2024; Gross profit: an increase of more than 70% as compared to the year ended December 31, 2024. The higher growth rate of gross profit relative to revenue demonstrates the effective optimization of the Group's products/services margins and its cost control capabilities; Net profit: an increase of more than 38% as compared to the year ended December 31, 2024, notwithstanding the adverse impact of foreign exchange and interest rate movements. The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or audited by the auditors of the Group or the audit committee of the Board. Shareholders and potential investors should refer to the annual results announcement of the Group for the year ended December 31, 2025, which is expected to be published on or about March 23, 2026. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$70.90, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 41x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 115% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$136 per share. Recent Insider Transactions Derivative • Nov 05
Company Secretary exercised options to buy HK$71m worth of stock. On the 28th of October, Xiaojie Xi exercised options to buy 1m shares at a strike price of around HK$4.89, costing a total of HK$4.9m. As of today, Xiaojie currently holds no shares directly. Company insiders have collectively sold HK$8.2m more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$71.85, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 46x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 203% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$41.72 per share. Reported Earnings • Sep 27
First half 2025 earnings released: EPS: CN¥0.62 (vs CN¥0.41 in 1H 2024) First half 2025 results: EPS: CN¥0.62 (up from CN¥0.41 in 1H 2024). Revenue: CN¥2.70b (up 62% from 1H 2024). Net income: CN¥745.7m (up 53% from 1H 2024). Profit margin: 28% (down from 29% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Hong Kong. Recent Insider Transactions Derivative • Sep 12
COO & Executive Director exercised options to buy HK$15m worth of stock. On the 5th of September, Jingwei Zhang exercised options to buy 220k shares at a strike price of around HK$4.89, costing a total of HK$1.1m. As of today, Jingwei currently holds no shares directly. Company insiders have collectively sold HK$13m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Sep 12
COO & Executive Director recently sold HK$14m worth of stock On the 9th of September, Jingwei Zhang sold around 220k shares on-market at roughly HK$64.26 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jingwei's only on-market trade for the last 12 months. Announcement • Sep 03
WuXi XDC Cayman Inc. has filed a Follow-on Equity Offering. WuXi XDC Cayman Inc. has filed a Follow-on Equity Offering.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,277,000
Transaction Features: Subsequent Direct Listing Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to HK$67.00, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 37x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 233% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$44.89 per share. Reported Earnings • Aug 20
First half 2025 earnings released: EPS: CN¥0.62 (vs CN¥0.41 in 1H 2024) First half 2025 results: EPS: CN¥0.62 (up from CN¥0.41 in 1H 2024). Revenue: CN¥2.70b (up 62% from 1H 2024). Net income: CN¥745.7m (up 53% from 1H 2024). Profit margin: 28% (down from 29% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Hong Kong. Buy Or Sell Opportunity • Aug 13
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 62% to HK$61.95. The fair value is estimated to be HK$49.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last 3 years. Earnings per share has grown by 67%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$50.25, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 26x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 237% over the past year. Announcement • Jul 10
WuXi XDC Cayman Inc. to Report First Half, 2025 Results on Aug 18, 2025 WuXi XDC Cayman Inc. announced that they will report first half, 2025 results on Aug 18, 2025 Announcement • Jun 27
WuXi XDC Cayman Inc. Announces Board and Board Committee Changes WuXi XDC Cayman Inc. announced that Dr. Weichang Zhou retired as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM to devote more time to his own personal commitments. Dr. Zhou has confirmed that he has no disagreement with the Board, and there are no matters relating to his retirement that need to be brought to the attention of the Shareholders or the Stock Exchange. The Board would like to express its sincere gratitude to Dr. Zhou for his valuable contribution to the Company during his tenure of service. The Board is also pleased to announce that Dr. Jijie Gu has been appointed as a non- executive Director with effect from the conclusion of the AGM. Dr. Jijie Gu (), aged 59, has been serving as President of Global Biologics Research and Chief Scientific Officer of WuXi Biologics since March 2019. Dr. Gu brings more than 20 years of drug research and development expertise and extensive management experience to the Company. He has significant expertise in target discovery, therapeutic design, protein engineering, preclinical drug discovery and early clinical development. Previously, Dr. Gu served as a function head at AbbVie Cambridge Research Center from August 2016 to March 2019, where he led target validation and lead discovery in AbbVie Immunology for both small and large molecule drugs. Before that, he was a function head of Oncology Biologics in Global Biologics at AbbVie Bioresearch Center from April 2012 to August 2016. While at Abbott/AbbVie, Dr. Gu made critical contributions to building antibody platform technologies. He led the construction of novel biologics platform technologies, including Fc engineering, ADC technology, TCR technology, bispecific and multispecific antibody technologies and T cell engagers. He also led projects in multiple therapeutic areas relating to oncology, immunology, immuno-oncology, metabolic disease, neuroscience and ophthalmology, and contributed broadly to AbbVie Biologics portfolio and delivered several New Biological Entities (NBEs) into clinical development. Throughout his extensive career, Dr. Gu has co-invented more than 20 filed and issued U. S. patents and has coauthored 40 publications. He currently serves on the editorial boards of the peer-reviewed journals Antibody Therapeutics. Dr. Gu obtained his Ph. D. in Molecular Biology and Biochemistry from Peking Union Medical School in July 1996. He received postdoctoral training in Tumor Immunology at the Dana Farber Cancer Institute in August 1999, a principal teaching affiliate of Harvard Medical School and in Cancer Cell Biology at the Harvard School of Public Health in February 2002. Dr. Weichang Zhou retired as a non-executive Director and a member of each of the Strategy Committee and the ESG Committee with effect from the conclusion of the AGM on June 27, 2025. The Board further announces that Dr. Jijie Gu was appointed as a member of each of the Strategy Committee and the ESG Committee and each of Ms. Ming Shi and Mr. Kenneth Walton Hitchner III was appointed as a member of the Nomination Committee, all with effect from June 27, 2025. Reported Earnings • May 02
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: CN¥0.89 (up from CN¥0.28 in FY 2023). Revenue: CN¥4.05b (up 91% from FY 2023). Net income: CN¥1.07b (up 277% from FY 2023). Profit margin: 26% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Hong Kong. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to HK$29.80, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 24x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 59% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$47.23 per share. New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Major Estimate Revision • Mar 31
Consensus revenue estimates increase by 11% The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from CN¥5.09b to CN¥5.65b. EPS estimate increased from CN¥1.02 to CN¥1.18 per share. Net income forecast to grow 33% next year vs 38% growth forecast for Life Sciences industry in Hong Kong. Consensus price target up from HK$38.36 to HK$48.62. Share price rose 5.5% to HK$44.40 over the past week. Buy Or Sell Opportunity • Mar 25
Now 23% undervalued Over the last 90 days, the stock has risen 27% to HK$40.00. The fair value is estimated to be HK$52.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last 3 years. Earnings per share has grown by 67%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Announcement • Mar 25
WuXi XDC Cayman Inc., Annual General Meeting, Jun 25, 2025 WuXi XDC Cayman Inc., Annual General Meeting, Jun 25, 2025. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$40.15, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 23x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 140% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$52.49 per share. Announcement • Mar 03
WuXi XDC Cayman Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025 WuXi XDC Cayman Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025 Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$35.60, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 26x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 92% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$52.49 per share. Major Estimate Revision • Jan 22
Consensus EPS estimates increase by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥3.35b to CN¥3.50b. EPS estimate increased from CN¥0.624 to CN¥0.70 per share. Net income forecast to grow 64% next year vs 64% growth forecast for Life Sciences industry in Hong Kong. Consensus price target up from HK$32.85 to HK$35.91. Share price fell 2.2% to HK$29.40 over the past week. Buy Or Sell Opportunity • Dec 16
Now 22% undervalued Over the last 90 days, the stock has risen 53% to HK$30.00. The fair value is estimated to be HK$38.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 135%. For the next 3 years, revenue is forecast to grow by 26% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$31.75, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 19x in the Life Sciences industry in Hong Kong. Total returns to shareholders of 8.9% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$38.55 per share. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to HK$23.35, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Life Sciences industry in Hong Kong. Simply Wall St's valuation model estimates the intrinsic value at HK$39.64 per share. Major Estimate Revision • Aug 27
Consensus EPS estimates increase by 32% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥3.16b to CN¥3.32b. EPS estimate increased from CN¥0.487 to CN¥0.642 per share. Net income forecast to grow 54% next year vs 38% growth forecast for Life Sciences industry in Hong Kong. Consensus price target down from HK$31.24 to HK$30.16. Share price was steady at HK$19.82 over the past week. Reported Earnings • Aug 24
First half 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.18 in 1H 2023) First half 2024 results: EPS: CN¥0.41 (up from CN¥0.18 in 1H 2023). Revenue: CN¥1.67b (up 68% from 1H 2023). Net income: CN¥488.2m (up 176% from 1H 2023). Profit margin: 29% (up from 18% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to HK$17.90, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 19x in the Life Sciences industry in Asia. Simply Wall St's valuation model estimates the intrinsic value at HK$32.33 per share. Announcement • Jul 29
WuXi XDC Cayman Inc. to Report First Half, 2024 Results on Aug 20, 2024 WuXi XDC Cayman Inc. announced that they will report first half, 2024 results on Aug 20, 2024 Valuation Update With 7 Day Price Move • May 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$18.42, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 24x in the Life Sciences industry in Asia. Announcement • May 01
WuXi XDC Cayman Inc., Annual General Meeting, Jun 12, 2024 WuXi XDC Cayman Inc., Annual General Meeting, Jun 12, 2024. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$16.76, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 24x in the Life Sciences industry in Asia. Reported Earnings • Mar 27
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: CN¥0.28 (up from CN¥0.18 in FY 2022). Revenue: CN¥2.12b (up 114% from FY 2022). Net income: CN¥283.5m (up 82% from FY 2022). Profit margin: 13% (down from 16% in FY 2022). The decrease in margin was driven by higher expenses. Products in clinical trials Phase I: 38 Phase II: 13 Phase III: 8 Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Announcement • Mar 14
WuXi XDC Cayman Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 WuXi XDC Cayman Inc. announced that they will report fiscal year 2023 results on Mar 25, 2024 Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to HK$16.20, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 24x in the Life Sciences industry in Asia. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to HK$16.66, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 21x in the Life Sciences industry in Asia. Announcement • Feb 03
WuXi XDC Cayman Inc. Provides Earnings Guidance for the Year Ended December 31, 2023 WuXi XDC Cayman Inc. provided earnings guidance for the year ended December 31, 2023. It is expected that the Group will record an increase of over 100% in revenue; an increase of over 80% in net profit; and an increase of over 100% in adjusted net profit, as compared with those for the corresponding period of last year. The Company considers that such expected increase was primarily attributable to the continuous active development of antibody-drug conjugate (``ADC'') industry and the Group's unique competitive strengths in winning projects. Board Change • Nov 20
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). CEO & Executive Director Jimmy Li is the most experienced director on the board, commencing their role in 2020. Independent Non-Executive Director Stewart Hen was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 
